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The present study aims to evaluate the in vitro and in vivo antileishmanial activities of Pistacia khinjuk Stocks (Anacardiaceae)
alcoholic extract and to compare its efficacy with a reference drug, meglumine antimoniate (MA, Glucantime), against Leishmania
tropica and Leishmania major. This extract (0–100 𝜇g/mL) was evaluated in vitro against promastigote and intracellular amastigote
forms of L. tropica (MRHO/IR/75/ER) and then tested on cutaneous leishmaniasis (CL) in male BALB/c mice with L. major to
reproduce the antileishmanial activity topically. In vitro, P. khinjuk extract significantly (𝑃 < 0.05) inhibited the growth rate
of promastigote (IC
50
58.6 ± 3.2 𝜇g/mL) and intramacrophage amastigotes (37.3 ± 2.5 𝜇g/mL) of L. tropica as a dose-dependent
response. In the in vivo assay, after 30 days of treatment, 75% recovery was observed in the infected mice treated with 30%
extract. After treatment of the subgroups with the concentration of 20 and 30% of P. khinjuk extract, mean diameter of lesions
was significantly (𝑃 < 0.05) reduced. To conclude, the present investigation demonstrated that P. vera extract had in vitro and in
vivo effectiveness against L. major. Obtained findings also provide the scientific evidences that natural plants could be used in the
traditional medicine for the prevention and treatment of CL.
1. Introduction
Cutaneous leishmaniasis (CL) is caused by the transmission
of Leishmania spp. through the bite of female sandfly. This
disease is characterized by chronic skin lesions and leaves
permanent scars as deformation of the infected area [1]. CL
is a public health problem with the annual incidence rate
of 1.5 million people throughout the world. According to
World Health Organization’s (WHO) report, 12 million peo-
ple are infected by parasites and 350 million people are
living in regions with the high risk of infection [2]. In Iran,
both epidemiological forms of this skin disease are present:
anthroponotic CL (ACL) and zoonotic CL (ZCL) caused by
Leishmania tropica and Leishmaniamajor, respectively [3]. At
present, the current medications used to treat leishmaniasis
such as meglumine antimoniate and sodium stibogluconate
are a challenge due to having problems of emerging resis-
tance, high toxicity, or high costs [4]. Since there is no
effective vaccine, maintenance and improvement of existing
treatment regimens, combined with new drug discovery
initiatives, were found to be the only ways to guarantee
continued control of CL [5].
Natural products, such as plants extract, either as pure
compounds or as standardized extracts, provide unlimited
opportunities for new drug discoveries because of the
unmatched availability of chemical diversity [6, 7].The genus
Pistacia belongs to the family Anacardiaceae. Among 15
known species of pistachios, only 3 species grow in Iran,
which include P. vera, P. khinjuk, and P. atlantica [8]. P.
khinjuk Stocks commonly grows in the Mediterranean and
Middle Eastern countries for the last 3000 years. In Iran, this
plant is called “khenjuk or kelkhong” and grows in the central,
western, and eastern areas [9]. Different parts of the plant
including resin, leaf, bark, fruit, and aerial parts have been
used widely as traditional medicine for the treatment and
prevention of various disease conditions such as stomach
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Figure 1: Pistacia khinjuk fruit which is called “kelkhong” in Iran.
discomfort, nausea, vomiting, and motion sickness [10]. In
addition, reviews have reported P. khinjuk to have anti-
inflammatory, antioxidant, antitumor, antiasthmatic, and
antimicrobial properties [8].The present study aims to evalu-
ate the in vitro and in vivo antileishmanial activity of P. khin-
juk extract and to compare its efficacy with a reference drug,
meglumine antimoniate (MA, Glucantime) against L. tropica
and L. major.
2. Materials and Methods
2.1. Chemicals. MA as a control drug was purchased from
Aventis, France. Penicillin and streptomycin were obtained
from Alborz Pharmacy, Karaj, Iran, and stored at room
temperature (25∘C) until testing. MTT powder [3-(4.5-
dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide],
fetal calf serum (FCS), fetal bovine serum (FBS), RPMI-1640
medium with L-glutamine, and Griess reagent (A and B)
were prepared from Sigma-Aldrich (St. Louis, MO, USA). All
other chemicals and solvents had the highest commercially
available purity.
2.2. Collection of Plant Materials. Fruits of P. khinjuk were
collected from rural regions of Kerman province, south east
of Iran, from May to September 2013 (Figure 1). They were
identified by a botanist of Botany Department of Shahid
Bahonar University of Kerman, Kerman, Iran. A voucher
specimen of the plant materials was deposited at the herbar-
ium of Department of Pharmacognosy, School of Pharmacy,
Kerman University of Medical Sciences, Iran (KF 1135).
2.3. Preparation of Extract. Air-dried plant materials (100 g)
were separately extracted by percolation method with 70%
aqueous ethanol successively for 72 h at room temperature.
The extracts were passed through filter paper (Whatman
number 3, Sigma, Germany) to remove plant debris. The
extracts were finally concentrated in vacuum at 50∘C using a
rotary evaporator (Heidolph, Germany) and stored at −20∘C
until testing [11].
2.4. Phytochemical Analysis. The preliminary phytochemical
analysis of the P. khinjuk ethanolic extract was carried out
to determine the presence of tannins, saponins, alkaloids,
flavonoids, and glycosides as described elsewhere using the
following reagents and chemicals [12]: alkaloids with Mayer
and Dragendorff ’s reagents, flavonoids with the use of Mg
and HCl, tannin with 1% gelatin and 10% NaCl solutions,
glycosides with FeCl
2
and H
2
SO
4
, and saponin with ability
to produce suds.
2.5. Parasite and Cell Culture. Standard strains of L. tropica
(MHOM/IR/2002/Mash2) and L. major (MRHO/IR/75/ER)
were kindly prepared from Center for Research and Training
in SkinDiseases and Leprosy, Tehran, Iran.Theparasites were
cultured at RPMI 1640 supplemented with penicillin
(200 IU/mL), streptomycin (100 𝜇g/mL), and 15% heat-
inactivated FCS. Murine macrophage cells (J774-A1) were
obtained fromPasteur Institute of Iran, Tehran, Iran.The cells
were cultured and maintained at Dulbecco’s modified eagle’s
medium (DMEM) supplemented with 10% FBS at 37∘C in
5% CO
2
.
2.6. Cytotoxic Effects. In order to determine the cytotoxic
effects of P. khinjuk, J774-A1 cells (5 × 105) were culti-
vated with various concentrations of alcoholic extract (0 to
5000 𝜇g/mL) in 96-well tissue culture plates at 37∘C in 5%
CO
2
for 48 h. Cell viability was determined by colorimetric
MTT assay and the results were displayed as the percentage
of dead cells compared to macrophages treated with MA and
nontreated macrophages (100% of viability) [13].
2.7. In Vitro Antileishmanial Activity
2.7.1. Antipromastigote Assay. To evaluate the antipromastig-
oteeffects of P. khinjuk ethanolic extract against promastigote
forms of L. tropica, colorimetric cell viability MTT assay
was used as described elsewhere [14]. At first, 100 𝜇L of the
promastigotes (106 cells/mL) harvested from logarithmic
growth phase was added to a 96-well tissue culture plate.
Then, 100 𝜇L of various concentrations of alcoholic extract
andMA (0–100 𝜇g/mL)was added to eachwell and incubated
at 25± 1∘C for 48 h. After the incubation, 10 𝜇L of MTT solu-
tion (5mg/mL) was added to each well and incubated at 25∘C
for 4 h. Promastigotes were cultured at complete medium
with no drug as positive control and complete medium
with no promastigotes and drugs as blank. The absorbance
was measured for each well at 560 nm using an ELISA reader
(BioTek-ELX800, USA).
2.7.2. Antiamastigote Assay. In this study, antiamastigote
activity of P. khinjuk extract was performed using the meth-
ods described by Mahmoudvand et al. [15]. Briefly, before
adding the macrophages to the plates, 1 cm2 cover slips were
placed in the wells of 6-chamber slides (Lab-Tek, Nalge Nunc
International, NY, USA). In the next step, 200 𝜇L of
macrophage (J774) cells (105/mL)was incubated at 37∘C in 5%
CO
2
for 2 h. Then, 200𝜇L (106/mL) promastigotes in sta-
tionary phase was added to the murine macrophages so that
proportion of Leishmania/macrophage was 10 : 1 and incu-
bated again in a similar condition for 24 h. Free parasites were
removed by washing with RPMI 1640 medium and the
infectedmacrophages were treated with 50𝜇L of various con-
centrations of 0–100 𝜇g/mL alcoholic extract at 37∘C in
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5% CO
2
for 72 h. Finally, the dried slides were fixed with
methanol, stained by Giemsa, and studied under a light
microscope. Also, the macrophages containing amastigotes
without extract and those with no parasite and extract were
considered positive and negative controls, respectively. Activ-
ity of anti-intramacrophage amastigotes of the extracts was
evaluated by counting the number of amastigotes in each
macrophage by examining 100 macrophages (% amastigotes
viability) in comparison with those obtained by positive
control.
2.7.3. Inhibition of Infection in Macrophage Cells. The
inhibitory effect of P. khinjuk extract against the promas-
tigotes invasion ofmacrophages, as one of themost important
pathogenic and biological criteria of Leishmania parasites,
was investigated. In this assay, promastigotes of L. tropica
were preincubated in P. khinjuk extract (5 𝜇g/mL) for 2 h at
room temperature. Then promastigotes were washed with
RPMI-1640mediumand incubatedwithmacrophage cells for
24 h. The macrophages were stained by Giemsa and studied
by a light microscope, to evaluate the frequency of infection
by counting 100 macrophages [3].
2.7.4. Nitric Oxide Production Determination. In this study,
nitric oxide (NO) release in supernatants of macrophage
culture was measured by the Griess reaction for nitrites
compared to the untreated macrophages. One hundred 𝜇L of
supernatants was collected 48 h after introducing the various
concentrations of P. khinjuk extract (3.125, 6.25, and 12.5) into
the culture medium.The assay was done in triplicate wells in
a 96-well tissue culture plate. To this, 60𝜇L of Griess reagent
A and then 60 𝜇L of Griess reagent B were added. The plates
were read at 540 nm in an ELISA plate reader (BioTek-
ELX800, USA).
2.8. In Vivo Antileishmanial Activity
2.8.1. Ethical Statement. The experimental procedures car-
ried out in this survey were in compliance with Guidelines
of Kerman University of Medical Science (Kerman, Iran) for
the care and use of laboratory animals in line with Animal
Ethics Committee (permit number 91/21).
2.8.2. Animals. Thirty-two male BALB/c mice (6–8 weeks
old) were obtained fromAnimal Breeding Stock Facility, Razi
Institute of Iran, Karaj, Iran. The animals were housed in a
colony room with a 12 : 12 h light/dark cycle at 21 ± 2∘C and
handled according to standard protocols for the use of
laboratory animals [16].
2.8.3. Infecting of BALB/c Mice by Injecting of L. major. To
infect the male BALB/c mice, 0.1mL of the promastigotes of
L. major (2 × 106 cells/mL) harvested from the stationary
phase was subcutaneously injected into the base of the tail
[17]. Thirty-two mice were divided into two groups; then,
every group was divided into two subgroups; so, every group
contained eight mice (Figure 2).
32 infected
mice
Group A (16 mice) Group B (16 mice)
A1
20% extract
(8 mice) (8 mice) (8 mice)
A2
control
(8 mice)
control
B1 B2
30% extract
Figure 2: Flow chart of in vivo antileishmanial activity of P.
khinjuk alcoholic extract after 30-day application as intralesionally
compared to meglumine antimoniate (MA) as control drug.
2.8.4. Treatment of Infected Mice. After 5 weeks when leish-
manial lesions appeared, the treatment of infected mice was
started. At first, the diameter of lesions was measured before
the treatment. Then, lotion (5 g/kg ethanolic extract at the
concentrations of 20 and 30%) and MA were applied for
each tested subgroup daily for 30 days topically. The control
subgroups received distilled water and ethanol topically.
2.8.5. Measurement of Lesion Size. Before and after the
treatment, the diameter of lesionswasmeasured using vernier
caliper in two diameters (𝐷 and 𝑑) at right angles to each
other, and the size (mm) was determined according to the
formula 𝑆 = (𝐷 + 𝑑)/2 [18].
2.8.6.Microscopical Examinations toDetermine Parasite Load.
Microscopical examinations were performed by laboratory
demonstration of the parasite load in the lesions by making
stained smears at the end of the experimental period. Lesions
were cleaned with ethanol and punctured at the margins
with a sterile lancet and exudationmaterial was smeared.The
smears were dried in air, fixed by methanol, and stained with
Giemsa to determine the load of parasites by lightmicroscopy
as follows:
negative: 0 parasite/10 fields,
1+: 1 parasite/10 fields,
2+: 1–10 parasites/10 fields,
3+: 10–100 parasites/10 fields,
4+: 1010–1000 parasites/10 fields,
5+ and more: more than 1000 parasites/10 fields.
2.9. Statistical Analysis. In this survey, all the tests were
carried out in triplicate. To determine CC
50
(cytotoxic con-
centration for 50% of cells) and IC
50
(50% inhibitory con-
centrations) lineal regression was used. Selectivity index (SI),
calculated based on the equation of CC
50
for murine
macrophage cells/IC
50
for amastigote forms of L. tropica, was
used to compare the toxicity and activity of ethanolic extract
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Table 1: Effect of various concentrations of P. khinjuk alcoholic extract before and after treatment on the size of lesions (cm) in Balb/c mice
infected by L. major.
Concentrations Size of lesions (cm) before treatment Size of lesions (cm) after treatment 𝑃 valueb
20% 1.31 ± 0.29 1.12 ± 0.20 <0.05
30% 1.28 ± 0.29 0.84 ± 0.12 <0.05
MAa 1.37 ± 0.22 0.42 ± 0.12 <0.05
Control 1.23 ± 0.25 2.09 ± 0.26 —
aMeglumine antimoniate.
bDifference is significant when compared to control.
of P. khinjuk, as described byWeniger et al. [19]. Data analysis
was carried out using SPSS statistical package, version 17.0
(SPSS Inc., Chicago, IL, USA). Differences between the test
and control groups were analyzed by 𝑡-test. In addition, 𝑃 <
0.05 was considered statistically significant.
3. Results
3.1. Phytochemical Analysis. In this study, the findings of
primary phytochemical screening of the ethanolic extract of
P. khinjuk demonstrated the presence of high amount of
tannins, phenols, and glycosides and lacking of the alkaloids
in this plant.
3.2. In Vitro Antileishmanial Effects
3.2.1. Antipromastigote Activity. The results revealed that P.
khinjuk alcoholic extract had remarkable antileishmanial
activity against the promastigote forms of L. tropica based on
a dose-dependent response (𝑃 < 0.05). IC
50
value for the P.
khinjuk extract and MA against promastigotes of L. tropica
was 58.6 ± 3.15 𝜇g/mL and 88.3 ± 4.05 𝜇g/mL, respectively.
3.2.2. Antiamastigote Assay. The findings demonstrated that,
similar to promastigote stage, P. khinjuk extract significantly
(𝑃 < 0.05) inhibited the growth rate of intramacrophage
amastigotes as a dose-dependent response.The obtained IC
50
values were 37.3 ± 2.51 𝜇g/mL and 44.6 ± 2.51 𝜇g/mL for the
P. khinjuk extract and MA, respectively.
3.2.3. Inhibition of Infection. The results revealed that pro-
mastigote forms of L. tropicawith no drugs were able to infect
84.3 ± 6.5 percent of macrophage cells. While promastigotes
treated with the P. khinjuk had potency to infect only 38.6 ±
3.05 percent of the macrophages cells, thus, these findings
revealed that infectivity of promastigotes of L. tropica sig-
nificantly reduced (𝑃 < 0.05) with P. khinjuk extract
preincubation.
3.2.4. NO Production Determination. The findings of this
assay demonstrated that the P. khinjuk at concentration of
3.125 𝜇g/mL triggered production of 14.3 ± 1.5 𝜇M of nitric
oxide compared to the untreated macrophages with value of
11.3 ± 0.5 𝜇M (𝑃 > 0.05), whereas this extract at higher
concentrations (≥6.25 𝜇g/mL) decreased production of NO
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Figure 3: Comparison of parasite load in tested groups after
treatmentwith various concentrations ofP. khinjuk alcoholic extract.
to ≤7 𝜇M, compared to the untreated macrophages (𝑃 >
0.05).
3.2.5. Cytotoxic Effects. In the assessment of in vitro cytotoxic
activity of alcoholic extract of P. khinjuk, it could be observed
that P. khinjuk extract had no significant cytotoxicity against
J774 cells. CC
50
values for P. khinjuk extract and MA were
511.6 ± 7.15 𝜇g/mL and 1225.6 ± 11.6, respectively. SI values
for the alcoholic extract P. khinjuk and MA are 13.7 and 27.5,
respectively.
3.3. In Vivo Antileishmanial Effects. In vivo antileishmanial
evaluation of the P. khinjuk alcoholic extract demonstrated
that, in the infected mice treated with the extract concen-
tration of 30%, the number of parasites significantly (𝑃 <
0.05) reduced with respect toMA, whereas 20% of the extract
decreased the number of parasites intermediately. Control
subgroups (distilled water and ethanol) had no decrease in
the number of parasites (Figure 3). After 30 days of treatment,
75 and 87.5% recovery were observed in the infected mice
treated with 30% extract and MA, respectively, while P. khin-
juk extract at the concentration of 20% recovered 50% of the
infectedmice. After treatment of the subgroups with the con-
centration of 20% P. khinjuk extract, mean diameter of lesions
was reduced to 0.19 cm. In contrast, in the subgroups treated
with 30% P. khinjuk extract, mean diameter of lesions was
decreased to 0.44 cm. In the positive subgroups, mean diam-
eter of the lesions was reduced to 0.77 cm (Table 1).
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4. Discussion
According toWHO,more than 80% of the world’s population
rely on traditional medicine for their primary healthcare
needs. In the past decades, the advent of synthetic antimicro-
bial drugs has caused reluctance in plants as a rich resource
for antimicrobial agents [20] However, in recent years, the
emergence of some limitations in the use of these drugs
has caused changes in the situation and interest in the field
of ethnobotanical research [21]. In the present investiga-
tion, the in vitro and in vivo antileishmanial activities of
alcoholic extract of P. khinjuk were assessed against L. tropica
and L. major. The obtained results of optical density (OD)
and consequently IC
50
values demonstrated that P. khinjuk
alcoholic extract significantly inhibited the growth rate of
promastigote forms of L. tropica. In addition, this extract sig-
nificantly decreasedmean infection rate and subsequently the
viability of amastigote forms in the macrophages compared
with the control group.Thefindings exhibited that amastigote
forms were more susceptible to P. khinjuk extract than
promastigote forms. This difference in the susceptibility of
promastigote and amastigote forms could be related to their
structural, biochemical, and morphological features as previ-
ously demonstrated by other researchers [22, 23]. In the in
vivo assay, it was found that P. khinjuk extract at the con-
centration of 30% had potent suppression effects on CL in
male BALB/c mice infected with L. major with 87.5% recov-
ery, whereas P. khinjuk extract at the concentration of 20%
displayed the suppression effects as intermediate. In line with
our results, it has been proven that gum obtained P. atlantica
controlled cutaneous leishmaniasis in mice infected with L.
major [24]. These results were in agreement with those of the
previous studies, indicating that the commonly used herbs
had antimicrobial properties that, in some cases, can be used
in traditional medicine [25]. Previously, in several studies,
antibacterial, antiviral, and antifungal effects of different parts
of Pistacia species, particularly P. khinjuk, have been demon-
strated [8]. However, there are few studies on the antiparasitic
effects of Pistacia species including the study conducted by
Orhan et al., which proved that P. vera branch extract at
the concentration of 4.8𝜇g/mL significantly (77.3%) inhibited
the growth of L. donovani, whereas dry leaf extract (PV-
DL) was active against Plasmodium falciparum (60.6% inhi-
bition) [26]. This research also revealed that the IC
50
values
of these extracts were determined as 2.3 𝜇g/mL for the amas-
tigotes of L. donovani grown at axenic culture and 3.65 𝜇g/mL
for P. falciparum.
The preliminary phytochemical analysis of P. khinjuk
extract demonstrated the presence of terpenoids, phenols,
flavonoids, fatty acids, and sterols and lack of alkaloids in this
plant. At present, individual activities of these compounds
have been proven [20]. Moreover, different studies have
shown potent antileishmanial activities of these compounds
such as terpenic derivatives, carvacrol, p-cymene, thymol,
carvone, limonene, and terpinene [27–30]. Therefore, the
presence of these phytoconstituents in P. khinjuk extract
could be responsible for their antileishmanial effect though
their exact mode of action is not clear. In the case of cytotoxic
effects, the present findings showed that P. khinjuk alcoholic
extract had no significant cytotoxic effects against J774 cells.
Furthermore, SI value ≥ 10 of P. khinjuk alcoholic extract
demonstrated its safety against the macrophage cells and
specificity to the parasite [19]. Thus, it can be suggested that
P. khinjuk alcoholic extract is safe for mammalian cells.
In conclusion, the findings of the present study demon-
strated that P. khinjuk alcoholic extract had potent antileish-
manial activity and could control cutaneous leishmaniasis in
mice infected with L. major. This result also provided the
scientific evidence that natural plants could be used in the
traditional medicine for the prevention and treatment of
cutaneous leishmaniasis.
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